Karman Holdings (KRMN) Q3 2026 Earnings Call Transcript

Karman Holdings reported Q3 revenue of $202 million, up 66% year over year, adjusted EBITDA of $61 million at a 30% margin, and record backlog of $1.7 billion. It raised 2026 guidance to $755–$760 million in revenue and $225–$227 million in adjusted EBITDA, while maintaining a 20%–25% organic growth target and approximately 30% margin outlook. Management cited strong defense demand and a $218 million, seven-year Lockheed Martin THAAD agreement, while flagging potential timing uncertainty in U.S. defense appropriations and working-capital cash demands.

Analysis

KRMN’s key investment question is no longer demand discovery but conversion: whether multiyear commitments become production revenue and cash without diluting its unusually high margin profile. Backlog quality is helped by binding orders, but its long-dated LTA component is not equivalent to near-term revenue visibility. The steepest THAAD ramp is expected in 2027, while the second-source qualifications are unlikely to matter financially before 2028. The market may be underpricing this lag if it capitalizes backlog as immediate growth; it may also underprice the option value of qualified capacity if production schedules hold.

The less obvious constraint is balance-sheet capacity. Rapid growth, elevated capex and acquisitions compete for cash while leverage remains high; a working-capital reversal or delayed customer collections could slow deleveraging even if EBITDA meets plan. A sustained 30% adjusted EBITDA margin is therefore a more important validation point than headline bookings. Verify cash conversion, contract assets/receivables, and the reconciliation of adjusted EBITDA to GAAP results. The stated margin confidence is management’s claim, not evidence that future LTA pricing will protect economics through inflation or execution issues.

Near term, appropriations uncertainty can delay order timing without eliminating underlying program demand; allied and commercial-space exposure provides some diversification, not a full offset. LMT’s THAAD agreement supports supply assurance for the program, but the disclosed contract alone does not establish a material change to LMT’s economics. Over 6–18 months, capacity expansion and second-source wins could extend KRMN’s competitive position; integration, control remediation and execution are counterweights. AI productivity remains an unproven option until measured in proposal throughput or engineering cost. No valuation or price data are provided, so the earnings signal is positive but insufficient to justify an unconditional momentum entry.

Key Decisions for Investors

• KRMN: Consider a staged long only after checking valuation against 2027 earnings expectations; add on evidence that the THAAD ramp converts to revenue while adjusted EBITDA margins remain near management’s target. Thesis weakens on a margin reset, missed guidance, or bookings/backlog failing to convert.
• Track quarterly operating cash flow and working-capital balances alongside EBITDA. If receivables or contract assets grow faster than sales, or leverage fails to decline as guided, reduce exposure: cash absorption could force slower investment or constrain further acquisitions.
• Treat the two second-source qualifications as a 2028+ catalyst, not a 2027 earnings driver. Seek confirmation of qualification timing, awarded scope and customer-funded capacity before assigning material value; failure to qualify or award would falsify the upside case.
• Watch congressional appropriations, prime-level quantity finalization and production schedules over the next 1–3 quarters. Delays may shift bookings and cash conversion; distinguish timing slippage from cancellations before trading the headline.